United States
BCMA (human), mAb (Vicky-1)
| ALX-804-151-C100 | 100 µg | 360.00 USD |  |
||
Replaces Prod. #: ALX-804-151/1
Product Specification
| Alternative Name: | B cell maturation protein, TNFRSF 17, CD269 |
| Concentration: | 1mg/ml |
| Formulation: | Liquid. In PBS containing 0.02% sodium azide. |
| Clone: | Vicky-1 |
| Isotype: | Rat IgG1 |
| Immunogen: | Recombinant human BCMA extracellular domain (aa 2-54) (Prod. No. ALX-522-026). |
| Source/Host: | Protein G-affinity purified. |
| Specificity: | Recognizes human BCMA. Does not cross-react with mouse BCMA. |
| Application: | ELISA Flow Cytometry Immunocytochemistry Functional Application (blocks binding of BAFF to human BCMA) Optimal conditions must be determined individually for each application. |
| Short Term Storage: | -20°C |
| Long Term Storage: | -20°C |
| Use/Stability: | Stable for at least 1 year after receipt when stored as recommended. |
| Handling: | Avoid freeze/thaw cycles. |
Figure: Immunostaining of HEK 293 cells transfected with a human BCMA expression plasmid (left panel), or mock transfected (right panel). Method: 3 days after transfection of cells with the indicated constructs, cells were fixed with acetone or 4% formaldehyde for 5 min. at room temperature. Slides were blocked with normal IgG, and incubated for 1 hour with 5µg/ml MAb to BCMA (human) (Vicky-1) (Prod. No. ALX-804-151) in 1% BSA in 1x PBS. After washes in PBS, samples were incubated with the secondary antibody for 1 hour, washed in PBS and revealed with StreptABComplex/HRP (Vector) and AEC.
Figure: Detection of endogenous human BCMA with MAb to BCMA (human) (Vicky-1) (Prod. No. ALX-804-151).Method: U266 cells (2x105) were incubated on ice for 30 min. with 0.2µg of MAb to BCMA (human) (Vicky-1) or an isotype control in 25µl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide). The primary antibody was revealed with PAb to Rat IgG (R-PE) and then analyzed by flow cytometry.
Please mouse over
Product Literature References
Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects: S. Koarada, et al.; Rheumatology (Oxford) 49, 662 (2010), Abstract; Full Text
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo: M.A. Lyu, et al.; Neoplasia 12, 366 (2010), Abstract;
TACI regulates IgA production by APRIL in collaboration with HSPG: D. Sakurai, et al.; Blood 109, 2961 (2007), Abstract;
General Literature References
BAFF AND APRIL: a tutorial on B cell survival: F. Mackay, et al.; Annu. Rev. Immunol. 21, 231 (2003), Abstract;
Product Toolbox
PRODUCT RESOURCES
Datasheet
RELATED PRODUCTS
By catalog section:
By biological activity:
BCMA Monoclonal antibodyPRODUCT SUPPORT
Technical ServiceBulk Quantity Quote
Customer Service
